LondonA decade of cancer immunotherapy progress has stalled.
Patients with treatment-resistant tumors now wait longer for next-generation drugs.
Researchers spent years copying one success instead of understanding how checkpoint drugs release tumors’ brake on T cells.
The review’s authors say the correction now costs years the field cannot easily recover.
Sources: Nature